UCSF Helen Diller Family Comprehensive Cancer Center | Strategic Alliance Partners

January 24, 2024

A review of how frequently adverse events from hyperphosphatemia to nail toxicities to stomatitis and more.

January 24, 2024

Provider perspectives on the importance of education patients about potential adverse events they may experience when initiating treatment with FGFR inhibitors.

January 20, 2024

A national survey conducted by UCSF researchers reveals that many physicians are unfamiliar with how the FDA regulates new drugs and medical devices.

January 18, 2024

Next-generation FGFR inhibitors show promise in early trials evaluating their efficacy and safety for the treatment of cholangiocarcinoma.

January 18, 2024

Experts discuss treatment options for cholangiocarinoma and how FGFR inhibitors have changed the treatment landscape in recent years.

January 10, 2024

Experts in treating cholangiocarcinoma share insights on when biomarker testing is needed and which biomarkers to test for.

January 10, 2024

Key opinion leaders illustrate how patients with intrahepatic cholangiocarcinoma present in a clinical setting.

January 10, 2024

The intricate web of risk factors influencing diverse forms of liver cancers are explored.

January 09, 2024

Thomas G. Martin, MD, has received a grant from the California Institute of Regenerative Medicine to produce a CAR T cell therapy for multiple myeloma.

December 29, 2023

The American Society of Clinical Oncology has elected Eric J. Small, MD, FASCO, to serve as its president for the term beginning in June 2025.

December 29, 2023

In case you missed it, here is a recap of the most popular episodes of OncLive On Air® from 2023.

December 25, 2023

Regular screenings may decrease the chance of diagnosis of advanced breast cancer in some women and lead to a 20% reduction in breast cancer mortality. However, the chances of being diagnosed with advanced breast cancer are higher among women who are Black or Hispanic/Latinx, overweight, or obese.

December 21, 2023

Laura A. Huppert, MD, discusses the impact of sequential treatment with fam-trastuzumab deruxtecan-nxki and sacituzumab govitecan-hziy on outcomes in patients with HER2-low metastatic breast cancer, according to findings from a retrospective analysis.

December 14, 2023

Medical experts discuss the pathology of intrahepatic cholangiocarcinoma.

December 13, 2023

University of California prostate cancer experts will share clinical insights at the first annual PSMA Conference, “PSMA PET and RLT: Present and Future.”

December 06, 2023

Pembrolizumab plus olaparib did not improve progression-free or overall survival vs pembrolizumab plus chemotherapy in patients with locally recurrent inoperable or metastatic triple-negative breast cancer who received induction pembrolizumab plus chemotherapy.

November 28, 2023

Arpita Desai, MD, discusses the impact that the findings from the phase 3 CONTACT-03 trial had in patients with metastatic renal cell carcinoma.

September 29, 2023

Ana Velázquez Mañana, MD, discusses findings from a study determining survivorship care needs in low-income, older patients with lung cancer.

September 28, 2023

Jacqueline Aredo, MD, MS, discusses findings from a study assessing the molecular distribution of driver mutations and tumor suppressor gene mutations in patients with non–small cell lung cancer who are eligible for lung cancer screening.

September 28, 2023

Andrew Ko, MD, FASCO, highlights what the potential approval of zolbetuximab could mean for the first-line treatment paradigm for patients with CLDN18.2-positive gastric/gastroesophageal junction adenocarcinoma and detailed other ongoing research in the gastrointestinal cancer space.